Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Shattuck Labs, Inc. STTK

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.0M
▼ 82.5% YoY
$-48.8M
$-40.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Our lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to DR3 and inhibit its interaction with its ligand, TL1A. In addition to SL-325 and SL-425 (a half-life extended version of SL-325), we are developing bispecific antibodies which co-target DR3 and other clinically validated targets in immune mediated and inflammatory diseases. We are currently conducting a single ascending dose (“SAD”) and multiple ascending dose (“MAD”) Phase 1 clinical trial evaluating SL-325 in healthy volunteers. We were incorporated in Delaware in May 2016.

Written from the business description in Shattuck Labs, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.

Growth

USD 1.0M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 1.0 · Net income -48.8
15M30M-50M-100M
201920222025
Compound annual growth
+15.3%
−36.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −36.8% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -5150.8% · Net ·
-5000%-10000%-15000%
201920222025
ROE
FY2025 · ROE -60.3%
-20%-40%-60%
201920222025
Three returns, three denominators.

Each USD of equity lost 60 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -40.0
-50M-100M
201920222025

Total assetsUSD 91.0M
EquityUSD 82.4M
CashUSD 54.2M
Current ratio11.70×

Equity funds 91% of total assets.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
STTK, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B0.00.00.00.00.00.00.0
Operating income $B−0.1−0.1−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.0−0.1−0.1−0.1−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.0
Net income $B−0.0−0.1−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.0−0.1−0.1−0.1−0.1−0.0−0.0
EPS, diluted $−0.70−1.49−2.05−2.41−1.07−2.36−3.17
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %−60.3−67.2−54.4−45.5−15.5——
Shares out B0.060.050.050.040.040.040.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 28 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 12 checks were skipped: EPS is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image